TSX Venture: QPT
EDMONTON, May 18, 2017 /CNW/ - Madenco Biosciences Inc.
("Madenco"), a subsidiary of Quest PharmaTech Inc. (TSX-V: QPT)
("Quest"), focused on bringing clinically validated products to the
consumer and dermatology market by utilizing proprietary
transdermal delivery technologies, announced today that they have
created the SP-DERM line of cosmeceuticals specifically targeting
applications that are demanded by dermatologists and medi-spas.
The SP-DERM line is based on Madenco's proprietary
SP-TechnologyTM platform that creates topically
deliverable molecules with superior properties in terms of skin
permeability or topical absorption. These molecules are also known
as protein transduction domain (PTD) or cell-penetrating
peptides/proteins (CPP).
Utilizing SP-Technology TM and with guidance from Dr.
Jaggi Rao MD, FRCPC, a respected
Edmonton dermatologist and
cosmetic surgeon, the following three products will mark the entry
of the SP-DERM line: (i) SP-DERM Recovery, a post-procedural cream
for promoting recovery after intensive laser treatments and/or
other procedures that leave the skin barrier compromised, (ii)
SP-DERM Maintenance, a maintenance cream for prolonging the effects
of cosmetic procedures and (iii) SP-DERM Acne, a serum to minimize
the appearance of acne scars.
A preliminary pilot study in patients suffering from acne scars
treated with SP-DERM Acne demonstrated improvement in both doctor
assessed and self-assessed results after 4 weeks and 8 weeks of
treatment with SP-DERM Acne.
"The result of this pilot study with SP-DERM Acne is encouraging
and warrants further controlled clinical study" said Dr.
Jaggi Rao. "If proven, SP-DERM
Acne could offer a unique effective therapeutic solution to
millions of acne sufferers".
"We are excited to collaborate with Dr. Rao to introduce
scientifically developed cosmeceuticals to dermatologists" said Dr.
Madi Madiyalakan, CEO of
Madenco/Quest. "SP-DERM will fill a much-needed market niche as
there is no current standard for post-procedural treatment or for
acne scar treatment in dermatology clinics. With over $12 billion spent annually on cosmetic procedures
in the U.S., there is a huge market potential for products like
SP-DERM that can enhance the benefits of cosmetic treatment in
dermatology clinics and spas as we continue to explore other
indications" added Dr. Madiyalakan.
Madenco has previously introduced Bellus Skin™ Serum to the
Canadian market, a clinically validated anti-aging skin serum
proven to reduce the appearance of wrinkles and signs of aging
using SP-TechnologyTM to deliver fusion proteins
targeting growth factors into the skin. Bellus Skin™ Serum is
available for purchase online at
www.bellusskin.com.
Madenco has also entered into sale agreements for Bellus Skin™
Serum in the European Union with a Swiss based company called HCBD
AG and for ASEAN countries with a Singapore based company, Merhati-Innokeys, and
is preparing its first shipment of product to Singapore this month.
About Madenco Biosciences Inc.
Madenco Biosciences is
a company specializing in developing products utilizing proprietary
transdermal delivery technologies with a focus on consumer and
dermatology markets. Madenco's first commercial cosmetic product is
Bellus Skin™ Serum, a clinically-proven anti-aging serum for people
over the age of 25, utilizing SP TechnologyTM to deliver
specific fusion proteins targeting growth factors to the skin,
helping to reduce the visible signs of aging.
About Quest PharmaTech Inc. (TSX-V: QPT)
Quest
PharmaTech Inc ("Quest" or the "Company") is a publicly traded,
Canadian based pharmaceutical company developing products to
improve the quality of life. The Company through its subsidiary,
OncoQuest is developing antibody based immunotherapeutic products
for cancer. In addition, the Company owns the Photodynamic Therapy
technology for oncology and dermatology applications, licensed to
BioCeltran Co., Ltd., a Korea based company (Bioceltran).
Quest has an ownership interest in Bioceltran which is focused on
SP Technology™ for transdermal delivery of drugs and
photosensitizers for pharmaceutical and cosmetic purposes. Quest
also markets consumer health products worldwide, including Bellus
Skin™ serum, a premium anti-wrinkle skin care product licensed from
Korea. Quest is also developing an antibody licensed from
University of Nebraska, Mab AR 9.6
against truncated O-glycan on MUC16, for targeted cancer therapy
applications.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For further information: Dr. Madi R.
Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc.,
Tel: (780) 448-1400 Ext. 204, Email: madi@questpharmatech.com
Internet: www.questpharmatech.com, www.madencobio.com,
www.bellusskin.com
SOURCE Quest PharmaTech Inc.